Highlights from interview with Wall Street Reporter (+ explanatory notes)
follow:
Propriety Products, primarily:
1a) Microderm - organic vision
technology - software to diagnose melanoma (NB organic vision technology
enables interpretation and comparison of scanned skin lesions to database to
enable diagnosis of skin cancer - accuracy trialed and equal to specialist
Dermatologists - database continually updated with latest research)
1b) Misdiagnosis of Melanoma estimated at Aus$700m - US much larger
1c) Approved in Aust & Europe - USA FDA applic this year - VSG
seeking one key strategic partner USA
2) Funhaler - (NB Asthma spacer device successfully trialed - improvement
in child's willingness to use medication, improvement in following/meeting
prescribed medication guidelines)
3) Organic vision is Visiomed's platform (proprietary) technology -
Visiomed is presently exploring opportunities to apply this technology to
successfully diagnose eye diseases
4) Visiomed is working collaboratively with Siemens Medical after having
acquired rights to distribute in Aust - VSG & Siemens are collaborating on
an ultrasound + organic vision technology to aid delicate spinal surgery
5) Value proposition - VSG's key differentiation is their platform
technology, i.e.; organic vision data and diagnostic aids such as their maiden
product, Microderm - VSG intends to leverage from this technology into other
medical diagnostic applications - scanning and expertly interpreting images to
diagnose the presence of other diseases, starting with skin cancer, then eye
disease, and exploring additional applications.
6) Dr Saliba Sassine - 16yrs biotech experience
7) Key Aust Siemens personnel now with Visiomed.
8) 2003 was year of consolidation - 2004 key milestones - FDA
approval of Microderm and Funhaler asthma spacer 2004 - co-development
of
medical imaging products with Siemens
9) 2004 has seen increased interest in adoption of software for medical
diagnosis - noticeable industry value shift
Regards,
Cris
Sent: Sunday, March 14, 2004 2:15
PM
Subject: [sharechat] Cris' Current
Watch List
Hi All,
As a fairly regular poster, I thought I'd share some of the more promising from my present
(evolving) watch list on the understanding it may be different again
tomorrow.
NB A good prospect today can be a bad prospect
tomorrow and vice versa depending on world events, good/poor business
planning and execution, changes in key executives (eg KAZ last year), etc,
etc, etc.
I consider all of the following to have high
growth potential. I'm reasonably sure all of these have been summarized
at varying times.
CBD - Maintain a vigil for best entry
price
INL - Wait a while for it to settle down again
IVN - May take a
while
MIC - Await confirmation of BioGold acquisition
MUL - Great
today, tomorrow, etc, etc (I researched this one following an excellent tip
from 'Oski' who posts occasionally to an Ozzie forum.)
NLX -
Hoping it will drop a little more to make it worthwhile
PDR - Promising a
return of capital to shareholders
SKG - Market has grown a little bored
with SKG of late
VSG - Long overlooked - ticking time bomb
WAL
- Great buy today, tomorrow, etc, etc
ZYL - Wait until it settles
after Rights Offer period.
All the above notations are naturally subject
to change of circumstances.
These shares have what I consider to be high
growth potential which usually goes hand-in-hand with high risk. I minimize
risk via research and tracking.
These shares are suited to a patient, long-term
hold. Time frames will be dependent upon market trends and
factors.
As always, I like to share info that may
bring benefit to someone else.
Regards,
Cris
See IRG research reports
